Editorial: severe colitis induced by targeted therapies in dermato-oncology beyond check point-inhibitors

Nassim Hammoudi^{1

2}, Matthieu Allez^{1

2}

Affiliations

¹ Université de Paris, INSERM U1160, EMiLy, Institut de Recherche Saint-Louis, Paris, France.
² Gastroenterology Department, AP-HP, Hôpital Saint-Louis, Lariboisière, Paris, France.

Editorial

Nassim Hammoudi et al. Aliment Pharmacol Ther. 2023 Apr.

. 2023 Apr;57(7):808-809.

doi: 10.1111/apt.17376.

Nassim Hammoudi^{1

2}, Matthieu Allez^{1

2}

¹ Université de Paris, INSERM U1160, EMiLy, Institut de Recherche Saint-Louis, Paris, France.
² Gastroenterology Department, AP-HP, Hôpital Saint-Louis, Lariboisière, Paris, France.

No abstract available

Comment on

Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors.
Carbonnel F, Routier E, Lazure T, Mussini C, Bellanger C, Merklen C, Bejou B, Buisson A, Amiot A, Meyer A, Dong C, Robert C. Carbonnel F, et al. Aliment Pharmacol Ther. 2023 Apr;57(7):792-799. doi: 10.1111/apt.17352. Epub 2022 Dec 28. Aliment Pharmacol Ther. 2023. PMID: 36578099

1. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26.
1. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-17.
1. Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018;67:2056-67.
1. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and Cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867-76.
1. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30-9.